Search Results

You are looking at 1 - 10 of 182 items for :

  • "hormone therapy" x
Clear All
Full access

Charles J. Ryan and Eric J. Small

Joyce R Fenton MA Rode P . High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy . J Urol 1998 ; 159 : 149 – 153 . 22 Kassouf W Tanguay S Aprikian A : Nilutamide as second line hormone therapy

Full access

Rowan T. Chlebowski, Aaron K. Aragaki and Garnet L. Anderson

Menopausal hormone therapy was introduced into clinical practice in the United States more than 60 years ago with the FDA approval of conjugated equine estrogen in the early 1940s. 1 When an increased risk of endometrial cancer was described

Full access

George Rodrigues, Himu Lukka, Padraig Warde, Michael Brundage, Luis Souhami, Juanita Crook, Fabio Cury, Charles Catton, Gary Mok, Andre-Guy Martin, Eric Vigneault, Jim Morris, Andrew Warner, Sandra Gonzalez Maldonado, Tom Pickles and the Genitourinary Radiation Oncologists of Canada (GUROC)

concomitant use of hormonal therapy. 5 Alternatives to dose-escalated external-beam radiotherapy include low-dose-rate (LDR) 6 and high-dose-rate (HDR) 7 brachytherapy (with or without integrated external-beam radiation therapy), hypofractionated radiation

Full access

Mindy E. Goldman

that in women who have sleep difficulties, this side effect of gabapentin may actually be a plus. As for hormonal therapy, “We know that hormones are the most effective therapy for treating vasomotor symptoms,” declared Dr. Goldman. Again, clinicians

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy and Cynthia X. Ma

therapy in the metastatic setting or at least 1 year from the completion of adjuvant hormone therapy. Palbociclib was considered second-line if received postprogression on a first-line therapy for MBC or on relapse at or within 1 year from the completion

Full access

Dawn Goetz

toxicities. 9 Therefore, much research has gone into developing other suitable therapies with potentially less toxicity. Hormone Therapies Archaically termed hormone-refractory (now CRPC) disease can respond to other hormone manipulation therapies

Full access

Presenter : William J. Gradishar

cells become resistant to antiestrogen therapy. With knowledge of these pathways, these targets became druggable, he said. Figure 2. Examples of hormonal therapies for ER+ breast cancer: evidence of recent acceleration. Abbreviations: AI, aromatase

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

will receive either endocrine therapy or no therapy. Those considered at average or high risk will receive either chemotherapy or combined chemo-hormonal therapy. The investigators predict that 27% more patients will be considered at low risk using the

Full access

Rodrigo Goncalves and Ron Bose

that the Onco type DX score predicted the likelihood of distant recurrence or breast cancer death when treated with hormonal therapy alone. 8 , 9 Archival samples from the NSABP B-14 trial, which tested the use of tamoxifen in patients with estrogen

Full access

Crystal S. Denlinger, Robert W. Carlson, Madhuri Are, K. Scott Baker, Elizabeth Davis, Stephen B. Edge, Debra L. Friedman, Mindy Goldman, Lee Jones, Allison King, Elizabeth Kvale, Terry S. Langbaum, Jennifer A. Ligibel, Mary S. McCabe, Kevin T. McVary, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Tracey O’Connor, Electra D. Paskett, Muhammad Raza, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole McMillian and Deborah Freedman-Cass

treatment, especially hormonal therapy and therapy directed toward the pelvis, can often impair sexual function. In addition, depression and anxiety, which are common in survivors, can contribute to sexual problems. Thus, sexual dysfunction is common in